Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,501–9,600 of 15,747
Stambouli, N., Bahrini, K., Romdhani, C., Rebai, A., Boughariou, S., Zakraoui, M., Arfaoui, B., Seyli, S., Boukhalfa, Y., Battikh, R., et al. (2024) · Journal of Immunological Methods · doi:10.1016/j.jim.2024.113665 · Cited by 4
Zhou, C., Qiu, Y., Wang, J., Zhong, X., Zhu, X., Huang, X., Yang, L., Ji, Q., Zhou, F., Wu, S., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2320913 · Cited by 5
Pareek, M., Sessa, P., Polverino, P., Sessa, F., Kragholm, K. H., & Sessa, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1210007 · Cited by 5
Predictors of real-world parents’ acceptance to vaccinate their children against the COVID-19
(2021) · doi:10.1101/2021.09.12.21263456 · Cited by 5
“The Coronavirus disease 2019 (COVID-19) pandemic continues to cause several problems at the individual, social and economic level, although from the beginning of 2021 there are several vaccines with proven safety and efficacy (Baden et al., 2021; Haas et al., 2021; Hall et al., 2021; Polack et al., 2020).”
BackgroundEfimov, S. V., Matsiyeuskaya, N. V., Boytsova, O. V., Akhieva, L. Y., Kvasova, E. I., Harrison, F., Karpova, Y. S., Tikhonov, A. A., Khomyakova, N. F., Hardman, T. C., et al. (2021) · Drugs in Context · doi:10.7573/dic.2020-11-1 · Cited by 7
Søfteland, J. M., Li, H., Magnusson, J. M., et al. (2024) · Viruses · doi:10.3390/v16020271 · Cited by 5
“Transplant patients were comparatively poorly protected from two doses of vaccines [15], but this was not common knowledge at the time since SOTRs were excluded from the initial vaccine trials [30,31].”
BackgroundKorosec, C. S., Farhang‐Sardroodi, S., Dick, D. W., Gholami, S., Ghaemi, M. S., Moyles, I. R., Craig, M., Ooi, H. K., & Heffernan, J. M. (2021) · medRxiv · doi:10.1101/2021.10.13.21264957 · Cited by 5
“In less than 8 months, the mRNA vaccines BNT162b2 (manufactured by PfizerBioNTech) and mRNA-1273 (manufactured by Moderna) were approved for emergency use in several countries [6, 7].”
BackgroundCovTransformer: A transformer model for SARS-CoV-2 lineage frequency forecasting
Feng, Y., Goldberg, E. E., Kupperman, M. D., Zhang, X., Lin, Y., & Ke, R. (2024) · Virus Evolution · doi:10.1093/ve/veae086 · Cited by 12
“Vaccination is an important and effective tool to reduce the level of transmission along with morbidity and mortality (Polack et al., 2020; Baden et al., 2021).”
Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2?
Iversen, P. L., & Bavari, S. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00149-3 · Cited by 5
The UK approach to COVID-19 vaccination: why was it so different?
English, P. M. B. (2021) · Drugs in Context · doi:10.7573/dic.2021-4-5 · Cited by 6
COVID-19 Vaccination: Does It Alter Postoperative Mortality and Morbidity in Hip Fractures?
Jagadeesh, N., Gnany, J., Kapadi, S., Koshy, N., & Shaw, D. (2022) · Cureus · doi:10.7759/cureus.32688 · Cited by 5
“According to preliminary results from phase III clinical trials, BNT162b2 and ChAdOx1-S vaccines are highly effective when administered in two doses at three-week and four-week intervals, respectively [15,16].”
BackgroundZhao, W., Sun, Y., Che, L., Wang, H., & Cao, A. (2025) · ChemMedChem · doi:10.1002/cmdc.202400832 · Cited by 5
Assessment of COVID-19 mRNA vaccination titer and side effects in healthy volunteers
Kozakai, R., Kushida, A., Moumouni, P. F. A. A., Okuma, S., Takahashi, K., Hoshi, K., Sato, Y. A., Takahashi, M., Chida, N., Takahashi, M., et al. (2022) · Journal of Laboratory Medicine · doi:10.1515/labmed-2021-0156 · Cited by 5
“BNT162b2 (Comirnaty; BioNTech/ Pfizer) is a lipid nanoparticle-formulated, nucleosidemodified mRNA vaccine for the prevention of COVID-19 [2].”
BackgroundInfluentialStollenwerk, N., Van-Dierdonck, J. B., Mar, J., et al. (2020) · medRxiv · doi:10.1101/2020.12.25.20248840 · Cited by 5
The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysisPreprint
Stoddard, M., Lin, Y., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2023) · medRxiv · doi:10.1101/2023.01.26.23285076 · Cited by 5
Utamura, M., Koizumi, M., & Kirikami, S. (2022) · Biology Methods and Protocols · doi:10.1093/biomethods/bpac023 · Cited by 5
Liu, D., An, C., Bai, Y., Li, K., Liu, J., Wang, Q., He, Q., Song, Z., Zhang, J., Song, L., et al. (2022) · Viruses · doi:10.3390/v14091854 · Cited by 5
Gervain, J., Szabó, K. B., Baki, E. H., Kadlecsik, L., Gyenesei, A., Herczeg, R., & Simon, J. (2021) · medRxiv · doi:10.1101/2021.05.16.21257288 · Cited by 5
“The rate of effectiveness after two vaccinations with BNT162b2 was 95% [8], and was confirmed at 85% against the more infectious and severe B.”
BackgroundSingh, S., Kumar, B. V., Jitender, Mishra, P. M., Verma, G., Kumar, S., Pandit, S., Kumar, R., Ringe, R. P., Tripathi, S., et al. (2024) · Process Biochemistry · doi:10.1016/j.procbio.2024.08.022 · Cited by 6
The demand for safety measures in the hospitality industry: Changes over three phases of a pandemic
Pennington-Gray, L. A., & Lee, S. (2024) · International Journal of Hospitality Management · doi:10.1016/j.ijhm.2024.103873 · Cited by 5
Reeves, D., Bracis, C., Swan, D. A., et al. (2021) · medRxiv · doi:10.1101/2021.02.02.21250985 · Cited by 2
Grebe, E., Yu, E. A., Bravo, M. D., Welte, A., Bruhn, R. L., Stone, M., Green, V., Williamson, P. C., Feldstein, L. R., Jones, J. M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac318 · Cited by 5
Yoshida, R., Sasaki, T., & Ohsaki, Y. (2024) · Cureus · doi:10.7759/cureus.61048 · Cited by 10
Advances in molecular adjuvants for nucleic acid vaccines
Hojecki, C. E., Tursi, N. J., Livingston, C., Weiner, D. B., & Gary, E. N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646800 · Cited by 5
Awareness and likelihood of accepting COVID-19 vaccines among the university students of Bangladesh
Hoque, A. F., Huq, S., Abdullah-Al-Shoeb, M., Mishu, M. A., & Azad, M. A. K. (2022) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v11i2.21280 · Cited by 6
Conducting Goals of Care Conversations: Lessons From the COVID-19 Pandemic
Lai, A. T., & Abdullah, N. (2023) · Journal of Palliative Care · doi:10.1177/08258597231153386 · Cited by 5
Bosch, A., Albero, S., Castillo, J. C., Ten, J., Guerrero, J., Ortiz, J. A., Bernabeu, A., & Bernabéu, R. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.01.002 · Cited by 5
Klimek, L., Novak, N., Hamelmann, E. H., et al. (2021) · Allergo Journal · doi:10.1007/s15007-021-4762-4 · Cited by 5
The Overlooked Stereoisomers of the Ionizable Lipid ALC315
De, C. K., Tsuda, M., Zhu, C., Dehn, S., Hinrichs, H., Tsuji, N., Jin, H., Arase, H., Tanaka, S., & List, B. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08345 · Cited by 8
Suspected COVID-19 mRNA Vaccine-Induced Postural Orthostatic Tachycardia Syndrome
Maharaj, N., Swarath, S., Seecheran, R. V., Seecheran, V. K., Panday, A., & Seecheran, N. A. (2023) · Cureus · doi:10.7759/cureus.34236 · Cited by 5
“These vaccines have demonstrated both clinical safety and efficacy against the virus [2].”
BackgroundOptimized biomimetic minerals maintain activity of mRNA complexes after long term storage
Choe, J. A., Brinkman, H. M., Lee, J. S., & Murphy, W. L. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.11.044 · Cited by 5
Rao, S., Bozio, C. H., Butterfield, K. A., Reynolds, S. B., Reese, S. E., Ball, S. W., Steffens, A., Demarco, M., McEvoy, C., Thompson, M. G., et al. (2022) · JMIR Formative Research · doi:10.2196/39231 · Cited by 5
Hu, J., Yuan, Z., Jiang, Y., & Mo, Z. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020359 · Cited by 6
Soto, A., Charca-Rodriguez, F. D. M., Pareja-Medina, M., Fernández-Navarro, M., Altamirano-Cáceres, K., Chávez, E. S., Raraz-Vidal, J., Cabezudo-Pillpe, N. E., Velarde-Rodríguez, M., & Alcántara-Díaz, A. M. (2021) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2021.384.9244 · Cited by 10
“The efficacy of these vaccines has been demonstrated to be in the range of 70 to 95% (7-10), showing immunogenicity comparable to that developed by convalescent patients (1,3,6,11,12).”
BackgroundAriyoshi, T., Hoshide, M., Motonaga, T., Korenaga, Y., Azuma, Y., Ichimura, T., Matsushige, T., & Hasegawa, S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2261167 · Cited by 5
Kobayashi, M., Mori, A., Oda, Y., Yokoyama, E., Kanaya, M., Izumiyama, K., Saito, M., Tanaka, S., Morioka, M., & Kondo, T. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03618-7 · Cited by 5
Vacunas SARS CoV-2, estudios en fase III
Guelfenbein, C. I., Torres, J. P., & de Pablo, M. E. S. (2021) · Revista chilena de infectología · doi:10.4067/s0716-10182021000100088 · Cited by 13
Vidales, E. P. R., Santos-Flores, J. M., Garza-Rodríguez, M. I., Salinas-Martínez, A. M., Martínez-Pérez, A. G., Montes‐de‐Oca‐Luna, R., & Marroquín-Escamilla, A. R. (2025) · Infectious Disease Reports · doi:10.3390/idr17050108 · Cited by 5
“AEFIs were more common after the first dose; however, receiving two or more doses increased the odds of various symptoms and hemorrhagic events, consistent with Polack et al. [3] and Lee et al. Less than 3% of AEFIs were serious, similar to Brazil and Argentina (3.7”
InfluentialTanishima, M., Ibaraki, K., Kido, K., Nakayama, S., Ata, K., Nakamura, H., Shinmura, Y., Endo, M., Sonoda, K., Ueda, K., et al. (2022) · medRxiv · doi:10.1101/2022.06.28.22276794 · Cited by 5
Risk of Death in Nursing Home Residents After COVID-19 Vaccination
Wouters, F., van Loon, A. M., Rutten, J. J. S., et al. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.08.013 · Cited by 5
Toutoudaki, K., Dimakakou, M., & Ανδρουτσάκος, Θ. (2023) · Vaccines · doi:10.3390/vaccines11020452 · Cited by 5
“These novel vaccines have proved to be safe and effective in a large variety of patients, including individuals with obesity, chronic lung disease, diabetes mellitus and cardiac disease, among others [35,36].”
BackgroundSharma, A., Prakash, J., & Ghosh, K. S. (2025) · Applied Research · doi:10.1002/appl.70043 · Cited by 5
An elite broadly neutralizing antibody protects SARS-CoV-2 Omicron variant challengePreprint
Zhou, B., Zhou, R., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Mok, B. W.-Y., Chen, B., Wang, P., Poon, V. K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.05.475037 · Cited by 7
He, X., Cao, Y., Lu, Y., Qi, F., Wang, H., Liao, X., Xu, G., Yang, B., Ma, J., Li, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181121 · Cited by 6
Symptom study app provides real-world data on COVID-19 vaccines
Drury, R. E., & O’Connor, D. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00264-4 · Cited by 5
Revilla‐Nebreda, D., Roncero‐Riesco, M., Santos-Briz, A. J., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17553 · Cited by 5
Andries, J., Viranaïcken, W., Cordonin, C., Herrscher, C., Planesse, C., Roquebert, B., Lagrange-Xélot, M., Kalamouni, C. E., Meilhac, O., Mavingui, P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10057-7 · Cited by 6
“Vaccinated individuals developed high neutralizing SARS-CoV-2 antibody titers which are indicators of COVID-19 protection 28,29 .”
BackgroundInfluentialTime-Varying Effectiveness of Three Covid-19 Vaccines in Puerto Rico
(2021) · doi:10.1101/2021.10.17.21265101 · Cited by 5
“Because the first term on the right is treated as known, if we assume β a (d) is a cubic-spline, then the model defined by (2) is reduced to a simple generalized linear model and we find the MLE β a (d) again using Iteratively Reweighted Least Square.”
MethodChest Pain and Suspected Myocarditis Related to COVID-19 Vaccination in Adolescents—A Case Series
Roh, D. E., Na, H., Kwon, J. E., Choi, I., Kim, Y. H., & Cho, H. J. (2022) · Children · doi:10.3390/children9050693 · Cited by 6
“However, as the safety of the COVID-19 vaccine was reassuring in adults, administering COVID-19 vaccines to adolescents and children became standard practice in many countries [5].”
BackgroundImmunisation against COVID-19 in Pregnancy and of Women Planning Pregnancy
Konje, J. C., Beloushi, M. A., & Ahmed, B. (2023) · Viruses · doi:10.3390/v15030621 · Cited by 7
Breastfeeding mother-child clinical outcomes after COVID-19 vaccination
(2021) · doi:10.1101/2021.06.19.21258892 · Cited by 5
“3% from the Pfizer-BioNTech COVID-19 trial.[3] Reassuringly, this was not associated with breast engorgement or mastitis.”
BackgroundResultInfluentialTsai, R., Hervey, J., Hoffman, K. D., et al. (2021) · medRxiv · doi:10.1101/2021.04.06.21254014 · Cited by 5
“(17, 18) Thus, with limited vaccine safety and efficacy data available, but noting the increased mortality risk, patients with comorbidities may have conflicted COVID-19 vaccine attitudes.”
BackgroundDevelopment of Methods to Produce SARS CoV‐2 Virus‐Like Particles at Scale
Edeling, M. A., Earnest, L., Montoya, J. C., Yap, A. H. Y., Mumford, J., Roberts, J., Wong, C. Y., Hans, D., Grima, J., Bisset, N., et al. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28937 · Cited by 5
“The first SARS ‐ CoV ‐ 2 vaccines to show impact were the lipid nano-particle encapsulated Spike encoding mRNA vaccines (Baden et al. 2021; Polack et al. 2020), which were delivered at historical speed (within approximately ten months of declaration of the pandemic) and were soon followed by…”
Espinar, A. L., Ru, E. C. L., Kumar, P., Soares, F., O’Driscoll, C. M., Darby, B. L., & Kowalski, P. S. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c03644 · Cited by 7
Blais, J. E., Wei, Y., Chui, C. S. L., Chan, E. W., & Wong, I. C. K. (2021) · Drug Safety · doi:10.1007/s40264-021-01108-5 · Cited by 5
Lindsey, K., Farrell, Z., Tutino, R., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127593 · Cited by 5
Jacobson, B. F., Schapkaitz, E., Takalani, A., Rowji, P., Louw, V. J., Opie, J., Bekker, L., Garrett, N., Goga, A. E., Reddy, T., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000302 · Cited by 5
Emerging lipid nanoparticle systems capable of efficient intramuscular RNA delivery
Raza, A., Zhang, R., Lu, R., Wen, J., & Wu, W. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2555507 · Cited by 9
Wei, C. Y., Zhu, Y., Lu, X., Goodier, K. D., Yu, D., Liu, X., Choy, J., Calderón, A. T., Su, Y., Ma, J., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01706-7 · Cited by 10
Watanabe, Y., Hosokawa, N., Yoshida, M., Miura, T., & Kawano, M. (2023) · Vaccines · doi:10.3390/vaccines11020287 · Cited by 5
“The large-scale, worldwide spread of SARS-CoV-2 in humans and the battle against the host immune responses resulted in the generation of viral mutations and the development of variant strains [1,2].”
BackgroundPadhi, B. K., Chakrapani, V., Gupta, M., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.994206 · Cited by 5
Predictors of a weak antibody response to COVID-19 mRNA vaccine in systemic lupus erythematosus
Parsons, C., Rubio, J., Boulougoura, A., Krishfield, S., & Kyttaris, V. C. (2023) · Rheumatology International · doi:10.1007/s00296-023-05347-w · Cited by 5
“COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) have demonstrated a high degree of effectiveness in preventing severe COVID-19 disease in healthy individuals [1, 2].”
BackgroundGoh, F. T., Chew, Y. Z., Tam, C. C., Yung, C. F., & Clapham, H. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100581 · Cited by 5
Bramer, L., Hontz, R. D., Eisfeld, A. J., Sims, A. M., Kim, Y., Stratton, K. G., Nicora, C., Gritsenko, M. A., Schepmoes, A., Akasaka, O., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13795 · Cited by 6
“Prior efforts towards identification of protective mechanisms have focused on adaptive immunity, and clearly showed that antibodies directed against SARS-CoV-2 Spike protein neutralize virus in natural infection and vaccine recipients [10 – 12].”
A Bibliometric Visualization Analysis on Vaccine Development of Coronavirus Disease 2019 (COVID-19)
Zeng, D., Wang, J., Xiao, B., Zhang, H., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines11020295 · Cited by 7
L’Huillier, A. G., Ardura, M. I., Chaudhuri, A., Danziger‐Isakov, L. A., Dulek, D. E., Green, M., Michaels, M. G., Posfay-Barbe, K. M., Vásquez, L., & Benden, C. (2021) · Pediatric Transplantation · doi:10.1111/petr.14031 · Cited by 5
Al-Matouq, J. A., Ali, M. D., Al-Somali, S. M., Ahmad, A., Banu, N., & Patel, M. (2022) · Infection Prevention in Practice · doi:10.1016/j.infpip.2022.100251 · Cited by 6
“[6,16,17, 34-37], whereas we found that side effects were more common amongst males.”
Yu, Y., Lau, J. T. F., & Lau, M. M. C. (2021) · Vaccines · doi:10.3390/vaccines9121414 · Cited by 4
“4% efficacy in preventing severe COVID-19 symptoms [21].”
BackgroundMatayoshi, K., Takahashi, S., Ryu, S., Koide, H., Yonezawa, S., Ozaki, N., Kurata, M., & Asai, T. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125485 · Cited by 5
Vaccination against COVID-19: a challenge in CLL
Eichhorst, B. F. (2021) · Blood · doi:10.1182/blood.2021011935 · Cited by 5
Hou, C., Williams, S. A., Taylor, K., Boyle, V., Bobbett, B., Kouvetakis, J., Nguyen, K., McDonald, A., Harris, V. K., Nussle, B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072627 · Cited by 5
Sindhi, R. K., Ashokkumar, C., Spishock, B., Saunders, M., Mabasa, A., Sethi, P., Reddy, A. P., & Nibhanupudy, B. (2021) · medRxiv · doi:10.1101/2021.05.21.21257442 · Cited by 6
“Line diagrams show mean ± SEM frequencies of S1- S2- and S-reactive CD4 cells (upper panel) and CD8 cells (middle panel) pre-vaccination (pre) after the first dose (1) and second dose (2) of mRNA vaccines.”
BackgroundKuzmina, A., Atari, N., Ottolenghi, A., Korovin, D., Cohen-Lass, I., Rosental, B., Rosenberg, E., Mandelboim, M., & Taube, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.26.489630 · Cited by 5
Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines
Kassianos, G. C., MacDonald, P., Aloysius, I., & Pather, S. (2024) · Vaccines · doi:10.3390/vaccines12010057 · Cited by 8
“The COVID-19 mRNA vaccine trials enrolled very large numbers of participants; the pivotal phase II/III clinical trial of BNT162b2 included more than 43,500 individuals, and the mRNA-1273 trial included more than 30,000 individuals [178,179].”
BackgroundErdoğan, A. P., Ekinci, F., Akçalı, S., & Göksel, G. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.05.021 · Cited by 5
“In the phase 3 study of the BNT162b2 vaccine, an efficacy of 95% was reported after two doses [5].”
BackgroundA Single-Chain Mpox mRNA Vaccine Elicits Protective Immune Response in Mice
Xu, Q., Zhang, R., Wu, M., et al. (2025) · Vaccines · doi:10.3390/vaccines13050514 · Cited by 5
“Several successfully developed COVID-19 mRNA vaccines employ LNP delivery technology, demonstrating the efficacy of LNPs in stabilizing mRNA and effectively delivering it into cells [12,14,15].”
Wen, K., Bai, C., Zhao, H., Zhou, P., Gao, S., Guan, H., & Song, M. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2022.2055806 · Cited by 6
Protocol for the economic evaluation of COVID-19 pandemic response policies
Chua, B. W. B., Huynh, V. A., Lou, J., Goh, F. T., Clapham, H., Teerawattananon, Y., & Wee, H. L. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051503 · Cited by 5
Kétoldali Parsonage–Turner-szindróma COVID–19-vakcinációt követően.
Lukács, K., Csöregh, É., & Fekete, B. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32546 · Cited by 5
Applications of Advanced ASOs, RNA Mimics, and Others in RNA-Based Therapeutics
Chakkyarath, V. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_3 · Cited by 5
New, J., Cham, J., Smith, L., Puglisi, L. H., Huynh, T. R., Kurian, S. M., Bagsic, S. R. S., Fielding, R., Hong, L. K., Reddy, P., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008233 · Cited by 4
Badaró, R. J. D. S., Novaes, G. C., Andrade, A. C., Neto, C. A. D. A., Machado, B. A. S., Barbosa, J. D. V., & Soares, M. B. P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1071239 · Cited by 9
“In total, two persons vaccinated with BNT162b2 died in the phase 2/3 study, one due to arteriosclerosis, and the other, by cardiac arrest (18).”
BackgroundZacharopoulou, E., Orfanoudaki, E., Tzouvala, M., Tribonias, G., Kokkotis, G., Kitsou, V., Almpani, F., Christidou, A., Viazis, N., Mantzaris, G. J., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac068 · Cited by 5
Sheng, A. Y., Gottlieb, M. A., Bautista, J. R., Trueger, N. S., Westafer, L. M., & Gisondi, M. A. (2023) · AEM Education and Training · doi:10.1002/aet2.10877 · Cited by 7
Augustinussen, M. H., Tylden, G. D., & Rinaldo, C. H. (2023) · Viruses · doi:10.3390/v15030619 · Cited by 7
Trabace, L., Pace, L., Morgese, M. G., Santo, I. B., Galante, D., Schiavone, S., Cipolletta, D., Rosa, A. M., Reveglia, P., Parisi, A., et al. (2022) · Viruses · doi:10.3390/v14040814 · Cited by 5
“Real-world data demonstrated 95% effectiveness of this mRNA-based vaccine against the original SARSCoV-2 and Alpha variant [10,11].”
MethodAlkadi, M. M., Hamad, A., Ghazouani, H., Elshirbeny, M. F., Ali, M. Y., Ghonimi, T. A. L., Ibrahim, R., Abuhelaiqa, E. A., Abou‐Samra, A., Al-Malki, H. A., et al. (2022) · Vaccines · doi:10.3390/vaccines11010049 · Cited by 5
The joint determination of morbidity and vaccination in the spatiotemporal epidemiology of COVID-19
Beenstock, M., Felsenstein, D., & Gdaliahu, M. (2023) · Spatial and Spatio-temporal Epidemiology · doi:10.1016/j.sste.2023.100621 · Cited by 5
Intawong, K., Chariyalertsak, S., Chalom, K., Wonghirundecha, T., Kowatcharakul, W., Thongprachum, A., Chotirosniramit, N., Noppakun, K., Khwanngern, K., Teacharak, W., et al. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.10.001 · Cited by 7
Liposomes - Recent Advances, New Perspectives and Applications
Tyagi, R. K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102167 · Cited by 6
Eisler, J. J., Disanto, G., Sacco, R., Zecca, C., & Gobbi, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175551 · Cited by 5
“Of these, 315 patients were vaccinated with mRNA vaccines by August 2022 (Pfizer = 207, Moderna = 95, unknown = 13; 5 with one dose, 67 with two doses, 220 with three doses and 23 with four doses) [16,17].”
BackgroundAn mRNA Vaccine for Herpes Zoster and Its Efficacy Evaluation in Naïve/Primed Murine Models
Jiang, L., Zhou, W., Liu, F., Li, W., Xu, Y., Liang, Z., Cao, M. Q., Hou, L., Liu, P., Wu, F., et al. (2025) · Vaccines · doi:10.3390/vaccines13030327 · Cited by 7
“…latent virus, potentially lowering PHN risk, and present safer administration for immunocompromised individuals and rapid adaptability to viral evolution [21,22]. mRNA technology offers many unique advantages over traditional methods as a cutting-edge platform in the new era of vaccine development.”
Zhou, C., Sun, M., Huang, X., Liu, P., Ouyang, Z., Wu, M., Yuan, L., Chen, J., Shu, W., Cao, T., et al. (2025) · hLife · doi:10.1016/j.hlife.2025.04.008 · Cited by 5
Can COVID-19 vaccines improve cardiovascular outcomes?
Kow, C. S., Ramachandram, D. S., & Hasan, S. S. (2022) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2022.102350 · Cited by 5
Mizoguchi, T., Yokoi, M., Shintani, Y., et al. (2022) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2022.04.020 · Cited by 5
“Although the safety and efficacy of BNT162b2 have been widely accepted [2], it is clinically important to know the potential risk of side effects.”
Yamaguchi, D., Shimizu, R., & Kubota, R. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13164 · Cited by 6
Bhatia, M. R., Putcha, V. R. P., Dwivedi, L. K., et al. (2021) · The International Journal of Community and Social Development · doi:10.1177/25166026211053485 · Cited by 5
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.